Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion

医学 阿柏西普 视网膜中央静脉阻塞 黄斑水肿 置信区间 视力 眼科 视网膜分支静脉阻塞 人口 贝伐单抗 外科 内科学 化疗 环境卫生
作者
Ramin Tadayoni,Liliana P Paris,Carl J. Danzig,Francis Abreu,Arshad M. Khanani,Christopher Brittain,Timothy Y. Y. Lai,Zdenka Hašková,Taiji Sakamoto,Aachal Kotecha,Patricio G. Schlottmann,Ying Liu,András Seres,Anne-Cecile Retiere,Jeffrey R. Willis,Young Hee Yoon
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:131 (8): 950-960 被引量:21
标识
DOI:10.1016/j.ophtha.2024.01.029
摘要

PurposeTo evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibitor, faricimab, compared with aflibercept in patients with macular edema due to retinal vein occlusion (RVO).DesignTwo identically designed, phase 3, global, randomized, double-masked, active comparator–controlled trials: BALATON (NCT04740905; N = 149 sites) and COMINO (NCT04740931; N = 192 sites).ParticipantsPatients ≥18 years of age with treatment-naïve foveal center-involved macular edema due to branch (BALATON) or central or hemiretinal (COMINO) RVO.MethodsPatients were randomized 1:1 to faricimab 6.0 mg or aflibercept 2.0 mg every 4 weeks for 24 weeks.Main Outcome MeasuresThe primary end point was the change from baseline in best-corrected visual acuity (BCVA) at week 24. Efficacy analyses included patients in the intention-to-treat population. Safety analyses included patients who received ≥1 dose of study drug.Results553 and 729 patients were enrolled in BALATON and COMINO, respectively. The BCVA gains from baseline at week 24 with faricimab were noninferior to aflibercept in BALATON (adjusted mean [95.03% confidence interval] change: +16.9 letters [15.7, 18.1] vs. +17.5 letters [16.3, 18.6]) and COMINO (+16.9 letters [15.4, 18.3] vs. +17.3 letters [15.9, 18.8]). Adjusted mean (95.03% confidence interval) central subfield thickness reductions from baseline were comparable for faricimab and aflibercept at week 24 in BALATON (−311.4 μm [−316.4, −306.4] and −304.4 μm [−309.3, −299.4]) and COMINO (−461.6 μm [−471.4, −451.9] and −448.8 μm [−458.6, −439.0]). A greater proportion of patients in the faricimab arm versus the aflibercept arm achieved absence of fluorescein angiography-based macular leakage at week 24 in BALATON (33.6% vs. 21.0%; nominal P = 0.0023) and COMINO (44.4% vs. 30.0%; nominal P = 0.0002). Faricimab was well tolerated, with an acceptable safety profile comparable with aflibercept. The incidence of ocular adverse events was similar between patients receiving faricimab (16.3% [n = 45] and 23.0% [n = 84] in BALATON and COMINO, respectively) and aflibercept (20.4% [n = 56] and 27.7% [n = 100]).ConclusionsThese findings demonstrate the efficacy and safety of faricimab, a dual Ang-2/VEGF-A inhibitor, in patients with macular edema secondary to RVO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
瓦学弟的妈妈关注了科研通微信公众号
3秒前
3秒前
4秒前
4秒前
5秒前
zhu发布了新的文献求助10
6秒前
zyx发布了新的文献求助10
6秒前
7秒前
8R60d8应助令狐惜海采纳,获得10
7秒前
巴纳拉完成签到,获得积分10
8秒前
天天开心发布了新的文献求助10
10秒前
11秒前
彭于晏应助sui采纳,获得10
11秒前
奶牛在吃豆完成签到,获得积分10
15秒前
CodeCraft应助jj采纳,获得10
16秒前
16秒前
16秒前
add完成签到 ,获得积分10
16秒前
17秒前
ding应助Coco采纳,获得10
19秒前
19秒前
bukeshuo发布了新的文献求助10
19秒前
无花果应助infognet采纳,获得10
19秒前
Rainbow7完成签到,获得积分10
20秒前
21秒前
nihaoxjm发布了新的文献求助10
21秒前
一个小太阳鸭完成签到,获得积分10
22秒前
内向苡完成签到,获得积分10
22秒前
妍妍发布了新的文献求助10
22秒前
23秒前
23秒前
共享精神应助狂野忆文采纳,获得10
23秒前
Owen应助狂野忆文采纳,获得10
23秒前
小蘑菇应助狂野忆文采纳,获得10
23秒前
23秒前
Jasper应助狂野忆文采纳,获得10
23秒前
斯文败类应助狂野忆文采纳,获得10
23秒前
研友_VZG7GZ应助狂野忆文采纳,获得10
23秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3958225
求助须知:如何正确求助?哪些是违规求助? 3504388
关于积分的说明 11118283
捐赠科研通 3235682
什么是DOI,文献DOI怎么找? 1788411
邀请新用户注册赠送积分活动 871211
科研通“疑难数据库(出版商)”最低求助积分说明 802565